Descriptive only
Acute pancreatitis
Metabolic dysfunction associated steatotic liver disease or steatohepatitis
longest follow-upRecorded harmsEach dose separatelyHazard ratio (from event counts)
2
Randomized trials
5
Treatments
408
Participants
0
Events
In plain language
No network meta-analysis was fitted here. The protocol requires at least two trials forming a connected network; this outcome has 2 trials. The trial data below are shown as reported.
Network of trials
Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.
Comparability of the trials
Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.
- FlagOutcome assessment, analysis set: confounded with design: randomized 1, safety 1
- NoteOutcome assessment, time point: selected time points span 52 to 56 weeks
| Trial | time weeks | analysis set | definition | instrument | adjudicated | proportion method | intercurrent events (discontinuation) | intercurrent events (rescue) | blinding | funding | start year | Eligibility |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SYNERGY-NASH | 56 | randomized | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2019 | age 18 to 80, BMI 27 to 50, biopsy MASH with NAS 4 or more and fibrosis F2 to F3, HbA1c up to 9.5 percent |
| NCT06309992 | 52 | safety | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2024 | age 18 or more; BMI 30 or more, or 27 with complication; MRI-PDFF 8 percent or more plus NIT or biopsy MASH |
Trial data
What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the hazard ratio (from event counts) on the analysis scale (log) against the trial's first row. Flags mark converted, combined or approximated inputs.
| Trial | Arm | Treatment | Week | Data | Value | SE | Events / N | Flags | Source |
|---|---|---|---|---|---|---|---|---|---|
| SYNERGY-NASH | A1 | TIRZ_SC_5MG_QW | 56 | arm, events | 0 / 47 | R0018381:Results | |||
| SYNERGY-NASH | A2 | TIRZ_SC_10MG_QW | 56 | arm, events | 0 / 47 | R0018381:Results | |||
| SYNERGY-NASH | A3 | TIRZ_SC_15MG_QW | 56 | arm, events | 0 / 48 | R0018381:Results | |||
| SYNERGY-NASH | A4 | PLACEBO | 56 | arm, events | 0 / 48 | R0018381:Results | |||
| NCT06309992 | A1 | SURV_SC_6p0MG_QW | 52 | arm, events | 0 / 146 | R0011245:Table 3 | |||
| NCT06309992 | A2 | PLACEBO | 52 | arm, events | 0 / 72 | R0011245:Table 3 |
Rerun this analysis yourself
Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.